Skip to main content
. 2014 Nov 24;33(6):567–574. doi: 10.1200/JCO.2014.56.2587

Fig 3.

Fig 3.

(A) Univariate analysis of overall survival of all patients by treatment with carboplatin-paclitaxel (CP) versus etoposide-cisplatin (EP). (B) Survival of a cohort of patients matched according to their propensity scores by treatment arm. (C) Survival of patients treated at EP-encouraging centers (enc) versus EP-discouraging centers (disc). (D) Survival of the near/far matched cohort.